Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-flow-chart

PFE Cash Flow

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) cash flow, as of Q4'25, shows strong performance with Operating Cash Flow reaching $5.35B USD and Free Cash Flow at $4.50B USD, indicating robust cash generation in the final quarter of the fiscal year. Over the period from Q1'23 to Q4'25, Operating Cash Flow exhibited volatility, fluctuating between a low of -$1.21B USD in Q2'23 and a high of $6.72B USD in Q3'24 and Q4'24, with consistent negative flows in Q2 quarters (e.g., -$1.78B USD in Q2'24 and -$582M USD in Q2'25) offset by strong recoveries in Q3 and Q4; overall, it trended upward with a cumulative positive bias, peaking in late-year quarters. Free Cash Flow followed a similar pattern, dipping to -$2.12B USD in Q2'23 and -$2.42B USD in Q2'24 before surging to $6.06B USD in Q3'24, reflecting capital expenditure impacts but demonstrating resilience and growth in core operations across the 12-quarter span.